ELHAM TAHERI: Open Payments
NPI 1023547320 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$482 in 18 payments from 11 companies in 2025. Trend: 2023 $985 · 2024 $1,076 · 2025 $482
Food & beverage: $482
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $137 |
| Novo Nordisk Inc | 5 | $100 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| ABBVIE INC. | 2 | $49 |
| PFIZER INC. | 1 | $26 |
| Becton, Dickinson and Company | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Abbott Laboratories | 1 | $20 |
| Amgen Inc. | 1 | $19 |
Products named: REXULTI, CAPLYTA, Rybelsus, Ozempic, QULIPTA, NURTEC ODT, BD MAX System, BD MAX Instrument, Auvelity.
Industry payments across VA — which companies pay providers there.
